Evidence map›Paper›PMID 34847708›Full record

SynthesisStroke2022

Dosage, Intensity, and Frequency of Language Therapy for Aphasia: A Systematic Review-Based, Individual Participant Data Network Meta-Analysis.

REhabilitation and recovery of peopLE with Aphasia after StrokE (RELEASE) Collaborators

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in Stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 9 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 9 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

REhabilitation and recovery of peopLE with Aphasia after StrokE (RELEASE) CollaboratorsListed in the Appendix.

Funding

RHDBank Database DevelopmentR01DC008524 · NIDCD · CARNEGIE-MELLON UNIVERSITY · PI BRIAN MACWHINNEY · 2007 to 2026
$7.0M
Post-Stroke Aphasia and rTMS Treatment (PART) StudyR01HD068488 · NICHD · UNIVERSITY OF CINCINNATI · PI SZAFLARSKI, JERZY P · 2012 to 2016
$2.5M
fMRI of Language Recover Following Stroke in AdultsR01NS048281 · NINDS · UNIVERSITY OF CINCINNATI · PI SZAFLARSKI, JERZY P · 2008 to 2012
$2.3M
Cognitive and Neural Basis of Functional Communication Deficits in Post-Stroke AphasiaR01DC017137 · NIDCD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MIRMAN, DANIEL, SZAFLARSKI, JERZY P · 2019 to 2023
$1.4M
A Preliminary Study of the Neurobiology of AAC-Induced Language Recovery in Post-Stroke AphasiaR15DC017280 · NIDCD · UNIVERSITY OF CINCINNATI · PI VANNEST, JENNIFER J. · 2018 to 2018
$495k
Department of HealthMedical Research Council MC_UU_00005/18Medical Research Council MR/M023672/1NICHD NIH HHS R01 HD068488NIDCD NIH HHS R01 DC008524NIDCD NIH HHS R01 DC017137NIDCD NIH HHS R15 DC017280NINDS NIH HHS R01 NS048281Wellcome Trust 205103/Z/16/Z
6 · The paper itself

Abstract

background and purposeOptimizing speech and language therapy (SLT) regimens for maximal aphasia recovery is a clinical research priority. We examined associations between SLT intensity (hours/week), dosage (total hours), frequency (days/week), duration (weeks), delivery (face to face, computer supported, individual tailoring, and home practice), content, and language outcomes for people with aphasia.

methodsDatabases including MEDLINE and Embase were searched (inception to September 2015). Published, unpublished, and emerging trials including SLT and ≥10 individual participant data on aphasia, language outcomes, and time post-onset were selected. Patient-level data on stroke, language, SLT, and trial risk of bias were independently extracted. Outcome measurement scores were standardized. A statistical inferencing, one-stage, random effects, network meta-analysis approach filtered individual participant data into an optimal model examining SLT regimen for overall language, auditory comprehension, naming, and functional communication pre-post intervention gains, adjusting for a priori-defined covariates (age, sex, time poststroke, and baseline aphasia severity), reporting estimates of mean change scores (95% CI).

resultsData from 959 individual participant data (25 trials) were included. Greatest gains in overall language and comprehension were associated with >20 to 50 hours SLT dosage (18.37 [10.58-26.16] Western Aphasia Battery-Aphasia Quotient; 5.23 [1.51-8.95] Aachen Aphasia Test-Token Test). Greatest clinical overall language, functional communication, and comprehension gains were associated with 2 to 4 and 9+ SLT hours/week. Greatest clinical gains were associated with frequent SLT for overall language, functional communication (3-5+ days/week), and comprehension (4-5 days/week). Evidence of comprehension gains was absent for SLT ≤20 hours, <3 hours/week, and ≤3 days/week. Mixed receptive-expressive therapy, functionally tailored, with prescribed home practice was associated with the greatest overall gains. Relative variance was <30%. Risk of trial bias was low to moderate; low for meta-biases.

conclusionsGreatest language recovery was associated with frequent, functionally tailored, receptive-expressive SLT, with prescribed home practice at a greater intensity and duration than reports of usual clinical services internationally. These exploratory findings suggest critical therapeutic ranges, informing hypothesis-testing trials and tailoring of clinical services. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42018110947.

Indexed as

AphasiaHumansLanguage TherapyStrokeStroke Rehabilitationaphasiabig datacomprehensionlanguage therapymeta-analysisstroke

Identifiers

PMID34847708
PMCPMC8884127
OpenAlexW3215472594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.